Terminated PHASE3 INTERVENTIONAL 2-arm NCT00207831

Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma (UFT RT Phase 3)

Trial UFT/RT Randomized Multicenter Phase III Randomized Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma

Sponsor: Institut Cancerologie de l'Ouest

Conditions M0 N0-2 Rectal Cancer Stage II/III T3 or T4 (Only Anal Extension) Rectal Cancer

Interventions Tegafur and Uracil

Updated 9 times since 2017 Last updated: Mar 23, 2020 Started: Jul 31, 2004 Primary completion: Jun 30, 2007 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated after interim analysis

Other terminated trials from Institut Cancerologie de l'Ouest

See all terminations from Institut Cancerologie de l'Ouest

This PHASE3 trial investigates M0 and N0-2 and is currently terminated or withdrawn. Institut Cancerologie de l'Ouest leads this study, which shows 9 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jun 2022 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jun 2022 [monthly]

Terminated PHASE3

▶ Show 4 earlier versions

Apr 2020 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2020 — Apr 2020 [monthly]

Terminated PHASE3
Jun 2018 — Feb 2020 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut Cancerologie de l'Ouest
Merck Sharp & Dohme LLC

Data source: Institut Cancerologie de l'Ouest

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Avignon, France , Bobigny, France , Brest, France , Brive-la-Gaillarde, France , Chartres, France , Clermont-Ferrand, France , Grenoble, France , La Roche-sur-Yon, France , Le Havre, France , Lille, France and 16 more locations